Pharmaceutical giant Pfizer has entered into a strategic research collaboration and licensing agreement with Enodia Therapeutics valued at upwards of…
Read More
Novartis Secures Strategic Partnership with Abogen to Advance Novel T-Cell Engager Therapies in Autoimmune Disease
The landscape of pharmaceutical partnerships continues to evolve at a rapid pace, marked by strategic alliances designed to tackle complex…
Read More
AstraZeneca Deepens Oncology Footprint with $2bn Equity Investment in Summit Therapeutics to Advance Next-Generation Cancer Combinations
AstraZeneca has announced a landmark $2bn equity investment in Summit Therapeutics, marking a major strategic alignment between the pharmaceutical giants…
Read More
Aptar Pharma and Macquarie University Partner in Three-Year Initiative to Advance Pulmonary Delivery of Biologic Medicines
Drug delivery specialist Aptar Pharma has announced a strategic three-year research collaboration with Macquarie University in Australia, aimed at optimizing…
Read More
Illumina TruPath Genome and DRAGEN Algorithm Unlock High-Resolution Analysis of Complex Genomic Regions in Landmark Whole-Genome Sequencing Advance
Genomic research has long faced a formidable bottleneck in deciphering the most complex regions of the human genome, particularly those…
Read More
Roche and Dualitas Therapeutics Ink Billion-Dollar Partnership to Advance Next-Generation Bispecific Antibodies in Immunology and Inflammation
In a landmark agreement that underscores the surging therapeutic potential of proximity biology, Swiss pharmaceutical giant Roche has joined forces…
Read More
Eli Lilly and Partner QurCan Therapeutics Form Strategic Alliance to Advance Next-Generation Genetic Medicines for Nervous System Disorders
The landscape of genetic medicine took a significant stride forward as pharmaceutical giant Eli Lilly and Company joined forces with…
Read More
Sling Therapeutics Secures $123M in Series C Financing to Advance Pivotal Phase III Trial of First-in-Class Oral TED Treatment
Sling Therapeutics has closed a significant $123 million Series C financing round, directing the capital toward the pivotal late-stage clinical…
Read More
Solstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy Porustobart
Solstice Oncology has successfully closed a landmark $225 million Series A funding round to accelerate the clinical development of its…
Read More
Exegenesis Bio and Modalis Therapeutics Join Forces in Strategic Licensing Agreement to Advance MDL-201 Gene Therapy for Duchenne Muscular Dystrophy
In a significant development for the field of genetic medicine, biotechnology innovators Exegenesis Bio and Modalis Therapeutics have formally announced…
Read More
